Decoy Therapeutics Inc.
NASDAQ Capital MarketTotal Valuation
Decoy Therapeutics Inc. carries a market capitalization of 1.43M, placing it among publicly traded companies globally.
| Market Cap | 1.43M |
| Enterprise Value | N/A |
Share Statistics
Decoy Therapeutics Inc. currently has 531,968.00 shares outstanding.
| Shares Outstanding | 531,968.00 |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.90 |
| P/TBV Ratio | 0.90 |
| P/FCF Ratio | -0.19 |
| P/OCF Ratio | -0.19 |
Financial Position
Decoy Therapeutics Inc. maintains a current ratio of 1.84, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.84 |
| Quick Ratio | 1.72 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -661.73 |
| Return on Assets (ROA) | -242.20 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Decoy Therapeutics Inc.'s stock has declined approximately -95.27075% over the past 52 weeks. The 50-day moving average sits at 4.66, while the 200-day moving average is 7.02.
| Beta (5Y) | N/A |
| 52-Week Price Change | -95.27075% |
| 50-Day Moving Average | 4.66 |
| 200-Day Moving Average | 7.02 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -13.17M, while operating income came in at -13.18M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -13.18M |
| Pretax Income | -13.03M |
| Net Income | -13.03M |
| EBITDA | -13.17M |
| EBIT | -13.18M |
| Earnings Per Share (EPS) | -66.97 |
Balance Sheet
Total book value stands at 3.88M, with working capital of 3.81M providing operational flexibility.
| Cash & Cash Equivalents | 7.82M |
| Total Debt | N/A |
| Net Debt | -7.82M |
| Equity (Book Value) | 3.88M |
| Book Value Per Share | 7.29 |
| Working Capital | 3.81M |
Cash Flow
Decoy Therapeutics Inc. produced -6.53M in operating cash flow over the past twelve months.
| Operating Cash Flow | -6.53M |
| Capital Expenditures | N/A |
| Free Cash Flow | -6.53M |
| FCF Per Share | -33.58 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -339.47 |
| FCF Yield | -514.17 |
Stock Splits
Decoy Therapeutics Inc.'s most recent stock split took place on March 9, 2026 with a 12:1 split ratio.
| Last Split Date | 3/9/2026 |
| Split Ratio | 12:1 |
Scores
Decoy Therapeutics Inc. posts an Altman Z-Score of -20.23, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -20.23 |